REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF DICYCLOMINE HYDROCHLORIDE, PARACETAMOL AND MEFENAMIC ACID IN BULK AND TABLET DOSAGE FORM

ESHA KHADGE1, SAVITA YADAV2, JAHNAVI RAO2**

1Department of Quality Assurance Techniques, Bharati Vidyapeeth University, Poona College of Pharmacy, Erandwane, Pune, India.
2Department of Pharmaceutical Chemistry, Bharati Vidyapeeth University, Poona College of Pharmacy, Erandwane, Pune, India.

© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i3.16351

ABSTRACT

Objective: The objective of this study was to develop and validate a simple, precise and accurate reverse phase high performance liquid chromatographic method for simultaneous estimation of dicyclomine hydrochloride, paracetamol, and mefenamic acid from multicomponent tablet dosage form.

Methods: The optimized chromatographic separation was achieved using a stationary phase of hypersil gold ODS-C18 (250 × 4.6 mm i.d, 5 μm particle size) column and mobile phase of acetonitrile: Methanol: Potassium dihydrogen phosphate buffer, pH adjusted to 4.5 with orthophosphoric acid (OPA) in the ratio of 50: 30: 20 (v/v/v) with a flow rate of 1 mL/minute. The ultraviolet detection was carried out at 260 nm.

Results: The retention times of paracetamol, dicyclomine hydrochloride and MEF were found to be 4.2, 6.1 and 3.4 minutes, respectively. The method was validated for linearity, precision, accuracy, and robustness. The developed method provided linear responses within the concentration ranges 2-12 µg/mL for dicyclomine hydrochloride, 50-300 µg/mL for paracetamol, and 25-150 µg/mL for MEF. The % recovery obtained were found to be 99.09-99.44% for dicyclomine hydrochloride, 99.22-99.51% for paracetamol, and 99.49-99.60% for MEF.

Conclusion: The proposed method enables rapid quantification and simultaneous analysis of all the drugs from commercial formulations without any interference of excipients. Hence, the developed method can be successfully applied for routine analysis of dicyclomine hydrochloride, paracetamol, and MEF in their combined tablet formulation.

Keywords: Dicyclomine hydrochloride, Paracetamol, Mefenamic acid, High performance liquid chromatography.

INTRODUCTION

Combination of dicyclomine hydrochloride (DCM), paracetamol (PARA), and mefenamic acid (MEF) are used for the treatment of periodic spasms, pain in abdomen, pain in stomach, intestinal cramps, irritable bowel syndrome, inability to control urine and other conditions. These drugs work by reducing muscle contractions and pain; increasing the pain threshold and increases the blood flow across the skin, heat loss, and sweating. Dicyclomine hydrochloride is a muscarinic antagonist used as an antispasmodic and in urinary incontinence. Chemically, dicyclomine hydrochloride is known as 2-(diethylamino) ethyl 1-cyclohexylcyclohexane-1-carboxylate; hydrochloride. Paracetamol is used to treat mild to moderate pain (from headaches, menstrual periods, toothaches, backaches, osteoarthritis, or cold/flu aches and pains) and to reduce fever. Paracetamol chemically is 4-acetaminophenol. MEF is nonsteroidal anti-inflammatory drugs used as antipyretics, analgesics, and anti-inflammatory agents. Chemically, MEF is 2-(2, 3-dimethylanilino) benzoic acid [Fig. 1a-c] [1-4].

Literature survey reveals that many spectrophotometric methods [5-10], high performance liquid chromatography (HPLC) [1-2,4], high performance thin layer chromatography [25-29], liquid chromatography-mass spectrometry [30], and GC [31] based methods have been reported for estimation of these drugs alone as well as in combination with other drugs in pharmaceutical dosage forms. Reversed phase (RP-HPLC) method offer significant economic advantages over the techniques cited above. Therefore, this work was aimed to develop and validate a new RP-HPLC method for simultaneous estimation of dicyclomine hydrochloride, paracetamol, and MEF in pharmaceutical dosage form.

METHODS

Chemicals and reagents
Blue Cross Laboratories Ltd., Goa kindly supplied gift samples of dicyclomine hydrochloride and MEF. Paracetamol gift sample was obtained from Molychem Manufacturers and Importers of Laboratory Reagents and Fine Chemicals, Mumbai. All chemicals and reagents used were of analytical grade and purchased from Merck Chemicals, India. CYCLOPAM PLUS tablet formulation containing dicyclomine hydrochloride 20 mg, paracetamol 500 mg, and MEF 250 mg was procured from local market.

Instrumentation
Chromatographic separation was achieved using HPLC system consisted of Intelligent HPLC pump model (Jasco PU 2080 plus), an autosampler and ultraviolet-visible (UV/VIS) (Jasco UV 2075 plus) detector. The output signal was monitored and processed using Jasco Borwin version 1.5, LC-Net II/ADC software. Hypersil gold ODS-C18 (250 mm, 4.6 mm id, 5 μm particle size) was used as the stationary phase. Mobile phase consisting acetonitrile: Methanol: Potassium dihydrogen phosphate buffer, pH adjusted to 4.5 with orthophosphoric acid (OPA) in the ratio of 50: 30: 20 (v/v/v) was delivered at a flow rate of 1 mL/minute. The detector was set at the wavelength of 260 nm. Injection volume was kept 20 µL.
Selection of wavelength
A UV spectrum of dicyclomine hydrochloride, paracetamol, and MEF in methanol was recorded by scanning the solution in the range of 200 nm to 400 nm. Dicyclomine hydrochloride, paracetamol, and MEF were showing significant absorption at wavelength 260 nm. Hence that was selected as the wavelength for analysis.

Preparation of standard stock solutions
A standard mixed stock solution of dicyclomine hydrochloride, paracetamol, and MEF was prepared by accurately weighing dicyclomine hydrochloride (20 mg), paracetamol (500 mg) and MEF (250 mg) into a 100 mL volumetric flask. The drugs were dissolved in aceton and the solution was diluted to volume. Stock solution was filtered through a 0.45 μm membrane filter. The stock solution was further diluted with mobile phase to obtain a solution of DCM (2 μg/mL), PARA (50 μg/mL) and MEF (25 μg/mL), respectively.

Preparation of sample solution
About 20 tablets of the pharmaceutical formulation CYCLOPAM PLUS (containing 20 mg of DCM, 500 mg of PARA and 250 mg of MEF) were assayed. They were crushed to a fine powder, and an amount of the powder equivalent to 20 mg of DCM, 500 mg of PARA and 250 mg of MEF was weighed and transfer in a 100 mL volumetric flask. The powder obtained was dissolved in aceton. The volumetric flask was sonicated for 15 min to effect complete dissolution of the DCM, PARA and MEF; the solution was then made up to volume with mobile phase. The solution was filtered through Whatman filter paper. The aliquot portion of the filtrate was further diluted to get a final concentration of 2 μg/mL of DCM 50 μg/mL of PARA and 25 μg/mL of MEF.

Method validation
The proposed method was validated for linearity, limit of detection (LOD) and limit of quantitation (LOQ), precision, accuracy and robustness as per International Conference on Harmonization (ICH) guideline [32].

Linearity
DCM (20 μg/mL), PARA (50 μg/mL) and MEF (250 μg/mL) stock solution was prepared, and it was diluted to prepare working standard solutions of 2-12 μg/mL of DCM, 50-300 μg/mL of PARA and 25-150 μg/mL of MEF, respectively. These solutions were injected in triplicate into the column, and the chromatograms were recorded with the optimized chromatographic conditions. The calibration curves of the area versus concentration were recorded for the three drugs.

LOD and LOQ
The method is said to be sensitive if it detects very low concentration of the analyte. It is based on the LOD and LOQ values. ICH guideline specifies three different types of methods to determine the LOD and LOQ values which include visual evaluation signal to noise ratio, and the standard deviation of response and the slope of the calibration curve. In the current study, the LOD and LOQ were based on the second approach and were calculated according to $S/N$ 3:1 and 10:1, respectively.

Precision
The precision of the method was determined by three independent injections of three different concentrations of each drug (4.8, 12 μg/mL for DCM, 100, 200, 300 μg/mL for PARA and 50, 100, 150 μg/mL for MEF), which were injected on the same day (intra-day precision or repeatability), and the values of relative standard deviation (% RSD) were calculated. The same concentration solutions were injected on different days to determine interday precision.

Recovery studies
The accuracy of the method, expressed in terms of recovery studies, was performed by standard addition method by adding known amount of drug to the real samples. Samples were suitably diluted and injected at each concentration levels in triplicate.

Robustness of method
The robustness of the developed method was determined by altering the experimental conditions such as flow rate, pH and percentage of methanol in mobile phase so as to check the deviation from the optimized chromatographic condition.

RESULT AND DISCUSSION
Optimized chromatographic conditions
The method development was finally optimized with the following conditions: Mobile phase consisting of acetonitrile: Methanol: Potassium dihydrogen phosphate buffer, pH adjusted to 4.5 with DPA in the ratio of 50:30: 20 (v/v/v) and hypersil gold ODS C-18 (250 mm × 4.6 mm; 5 μm particle size) column as stationary phase. The analysis was carried out in an isocratic elution mode using a flow rate of 1.0 mL/min, injection volume of 20 μL at room temperature, and the detection of analyte was recorded at 260 nm. The mobile phase solvents were filtered through 0.45 μm membrane filter before delivering into the HPLC system. The selectivity of the method was performed by injecting the dfluents and the mobile phase for any coeluting peaks, at retention times (Rt) of PARA, DCM and MEF were found to be 4.2, 6.1 and 3.4 minutes, respectively. The peak shape of all the drugs was satisfactory and suitable. Typical chromatograms are shown in Fig. 2 performance liquid chromatography chromatogram of dicyclomine, Paracetamol and mefenamic acid.

System suitability
The system suitability test plays an important role in the development of chromatographic method; it was used to insure that, the system is working correctly. There are system suitability parameters such as Rt, peak area, theoretical plates (N), and tailing factor were checked. This test was performed during development of the method. This test was performed by injecting the standard mixture in 5 replicates (Table 1).

Validation of the developed HPLC method
Linearity
The linearity range was established at 2-12 μg/mL for DCM, 50-300 μg/mL for PARA and 25-150 μg/mL for MEF. The linear regression equations were $Y = 11203X + 90.78 \ (r^2 = 0.998)$ for DCM,
Fig. 2: High performance liquid chromatography chromatogram of dicyclomine, PARA and mefenamic acid

**Fig. 3: Calibration curve of dicyclomine**

\[ Y = 44412X - 10223 \ (r^2 = 0.998) \]

**Fig. 4: Calibration curve of Paracetamol**

\[ Y = 11478X - 11071 \ (r^2 = 0.997) \]

**Fig. 5: Calibration curve of mefenamic acid**

Y = 44412X - 10223 (r² = 0.998) for PARA and Y = 11478X - 11071 (r² = 0.997) for MEF. The plots obtained from linear regression are given in Figs. 3-5 for DCM, PARA and MEF, respectively.

**LOD and LOQ**
The LOD and LOQ were found to be 0.4 μg/mL and 1 μg/mL for DCM, 15 μg/mL and 48 μg/mL for PARA and 5 μg/mL and 16 μg/mL for MEF, respectively, which indicate that the method was sensitive.

**Precision**
The intra- and inter-day precision studies showed a % RSD for DCM, PARA and MEF was <2%, respectively, which proved the method was sufficiently precise (Table 2).

**Accuracy**
Accuracy of the method was determined by applying the proposed method to synthetic mixture containing known amount of each drug to 80%, 100%, and 120% of the label claim. The % recovery obtained was found to be in the range of 99.09-99.44% for DCM, 99.22-99.51% for PARA, and 99.49-99.60 for MEF. The results were summarized in Table 3.

**Robustness**
Robustness studies were conducted by adjusting flow rate (±0.1 mL/minute), percentage of methanol in mobile phase (±1%), and pH of buffer (±0.1). On changing these chromatographic conditions, the method was proven to be robust as there was no greater deviation in the Rt and peak shape (Table 4).

**Analysis of the marketed formulation (assay)**
The developed method was applied for the determination of DCM, PARA and MEF in tablet dosage form. The obtained result for DCM, PARA and MEF was comparable with a corresponding label claim. The % content...
Khade et al.

Asian J Pharm Clin Res, Vol 10, Issue 3, 2017, 393-397

A simple, accurate, and specific RP-HPLC method has been developed for quantitative determination of dicyclomine hydrochloride, paracetamol, and MEF in bulk and pharmaceutical dosage form. The method was duly validated using required statistical parameters. From these results, it can be concluded that the proposed method is quite precise and accurate. The absence of additional peaks in the chromatogram indicated that there is no interference of the common excipients used in the tablets. The proposed HPLC method is sensitive and repeatable for the analysis of dicyclomine hydrochloride, paracetamol, and MEF in tablet dosage form.

ACKNOWLEDGMENT

The authors would like to thank, Blue Cross Laboratories Ltd., Goa and Molychem Manufacturers and Importers of Laboratory Reagents and Fine Chemicals, Mumbai, India for providing a gift sample of standard dicyclomine hydrochloride, MEF, and paracetamol. The authors would like to thank, Dr. K R Mahadik, Principal, Poona College of Pharmacy, Pune, India, for providing necessary facilities to carry out the work.

REFERENCES

1. Available from: http://www.tabletwise.com/cyclopam-plus-tablet.
2. Available from: http://www.healthdictionary.info/dicyclomine_hydrochloride.html.
3. Available from: https://www.drugs.com/cdi/mefenamic-acid.html.
4. O’Neill MJ, editor. The Merck Index. 13th ed. New Jersey: Merck and Co. Inc.; 2006. p. 545-1036.
5. Ragunath M, Dhamne A, Patil J. Simple UV spectrophotometric method for estimation of dicyclomine hydrochloride in bulk and tablet formulation. Asian J Pharm Clin Res 2010;4(2):109-13.
6. Sharma H, Kamrili V, Kumar KV, Dangi NB. Validated UV-spectrophotometric absorbance correction method for simultaneous estimation of paracetamol, paniubrom and dicyclomine hydrochloride in bulk and pharmaceutical dosage form. World J Pharm Pharm Sci 2015;4(8):1019-30.
7. Ragunath M, Dhamne A, Mistry V, Bhaskar V. Validated UV-spectrophotometric method for estimation of fixed dose combination of ciprofloxacin, tinidazole and dicyclomine in bulk and tablet formulation. World J Pharm Pharm Sci 2015;4(3):1117-27.
8. Roosewelt C, Harihrishnan N, Gunasekaran V, Chandrasekaran S, Haribaskar V, Prathap B. Simultaneous estimation of drotaverine HCl and mefenamic acid in tablet dosage form using spectrophotometric method. Asian J Chem 2010;22(2):843-9.
9. Dinc E, Cesoy C. Simultaneous spectrophotometric determination of mefenamic acid and paracetamol in a pharmaceutical preparation using ratio spectra derivative spectrophotometry and chemometric methods. J Pharm Biomed Anal 2002;28(6):1091-100.
10. Sireesha T, Kumari KS, Sai RV, Naik KS. Development and validation of a simple, accurate, and precise HPLC method for the analysis of dicyclomine hydrochloride, paracetamol, and MEF in bulk and pharmaceutical dosage form. J Pharm Biomed Anal 2002;28(6):1091-100.

Table 2: Precision studies

| Concentration (µg/mL) | Intra-day precision (n=3) | Inter-day precision (n=3) |
|-----------------------|---------------------------|--------------------------|
|                       | Measured concentration (%) RSD | Recovery (%) | Measured concentration (%) RSD | Recovery (%) |
| DCM 4                | 3.97                      | 1.08        | 99.25                  | 3.969        | 1.14       | 99.23 |
| 8                    | 7.96                      | 1.10        | 99.50                  | 7.97         | 1.10       | 99.63 |
| 12                   | 11.92                     | 1.07        | 99.33                  | 11.90        | 1.11       | 99.17 |
| PARA 100             | 5.09                      | 1.10        | 99.09                  | 5.09         | 1.09       | 99.05 |
| 200                  | 198.8                     | 1.09        | 99.40                  | 198.5        | 1.12       | 99.25 |
| 300                  | 297.5                     | 1.03        | 99.17                  | 297.2        | 1.04       | 99.07 |
| MEF 50               | 49.8                      | 1.08        | 99.60                  | 49.5         | 1.14       | 99.00 |
| 100                  | 99.07                     | 1.01        | 99.07                  | 99.02        | 1.15       | 99.02 |
| 150                  | 148.9                     | 1.19        | 99.27                  | 148.7        | 1.07       | 99.13 |

Table 3: Accuracy (n=3)

| Drug  | Level of recovery (%) | Amount present (mg) | Amount of drug added (mg) | Total amount (mg) | Amount recovered | % recovery |
|-------|-----------------------|---------------------|--------------------------|------------------|-----------------|------------|
| DCM   | 80                    | 20                  | 16                       | 36               | 35.8            | 99.44      |
|       | 100                   | 20                  | 40                       | 90               | 39.7            | 99.25      |
| PARA  | 80                    | 500                 | 40                       | 900              | 893.0           | 99.22      |
|       | 100                   | 24                  | 44                       | 100              | 99.51           | 99.91      |
|       | 120                   | 600                 | 110                      | 1100             | 1092.7          | 99.27      |
| MEF   | 80                    | 250                 | 450                      | 500              | 447.7           | 99.49      |
|       | 100                   | 250                 | 500                      | 498.0            | 99.60           |            |
|       | 120                   | 300                 | 550                      | 547.3            | 95.51           |            |

Table 4: Robustness of method

| Chromatographic factors | Level | Rt (minute) |
|-------------------------|-------|-------------|
| Flow rate (mL/min)      |       | DCM | PARA | MEF  |
| 0.9                     | -0.1  | 4.31| 3.52| 6.31 |
| 1                       | 0.0   | 4.2 | 3.4 | 6.1  |
| 1.1                     | +0.1  | 4.06| 3.31| 6.03 |
| % of methanol           |       |     |     |     |
| 29                      | -1    | 4.38| 3.58| 6.17 |
| 30                      | 0.0   | 4.2 | 3.4 | 6.1  |
| 31                      | +1    | 4.1 | 3.35| 6.06 |
| pH of buffer            |       |     |     |     |
| 4.4                     | -0.1  | 4.12| 3.37| 6.06 |
| 4.5                     | 0.0   | 4.2 | 3.4 | 6.1  |
| 4.6                     | +0.1  | 4.32| 3.44| 6.18 |

was calculated and found to be 99.57%, 99.71%, and 99.64% for DCM, PARA, and MEF, respectively.

CONCLUSION

A simple, accurate, and specific RP-HPLC method has been developed for quantitative determination of dicyclomine hydrochloride, paracetamol and MEF in bulk and pharmaceutical dosage form. The method was duly validated using required statistical parameters. From these results, it can be concluded that the proposed method is quite precise and accurate. The absence of additional peaks in the chromatogram indicated that there is no interference of the common excipients used in the tablets. The proposed HPLC method is sensitive and repeatable for the analysis of dicyclomine hydrochloride, paracetamol, and MEF in tablet dosage form.
of new analytical methods for the simultaneous estimation of paracetamol and dicyclomine hydrochloride in bulk and pharmaceutical dosage forms by using RPHPLC and UV methods. World J Pharm Res 2014;3(10):584-602.

11. Bachani MH, Acharya DS, Shah KV. Development and validation of HPLC method for simultaneous estimation of dicyclomine hydrochloride, acetaminophen and clindinium bromide in solid dosage form. Int J Pharm Pharm Sci 2013;5 Suppl 2:462-6.

12. Shah DA, Rana JP, Chhalotiya UK, Baldania SL, Bhatt KK. Development and validation of a liquid chromatographic method for estimation of dicyclomine hydrochloride, mefenamic acid and paracetamol in tablets. Indian J Pharm Sci 2014;76(6):529-34.

13. Donda ST, Baviskar VB, Deshmukh PK, Bari SB, Patil PO. Development and validation of a reversed-phase HPLC method for the simultaneous estimation of dicyclomine hydrochloride and famotidine in bulk and tablets. J Chil Chem Soc 2014;59(4):2662-5.

14. Sharma H, Kammili V, Kondreddy VK, Bhatta HP. Validated RP-HPLC method for simultaneous estimation of paracetamol, pamabrom and dicyclomine hydrochloride in bulk and pharmaceutical dosage form. Int J Pharm Sci Res 2016;7(1):316-24.

15. Kantariya B, Agola A, Roshani H, Ghetia U, Shivam SS. Development and validation of a RP-HPLC method for the simultaneous estimation of ranitidine hydrochloride and dicyclomine hydrochloride in tablet dosage forms. Int J Pharm Res Sci 2013;2(2):258-67.

16. Rouini MR, Asadipour A, Ardakani YH, Aghdasi F. Liquid chromatography method for determination of mefenamic acid in human serum. J Chromatogr B Analyt Technol Biomed Life Sci 2004;800(1-2):189-92.

17. Badgujar MA, Mangaonkar KV. Simultaneous determination of paracetamol and mefenamic acid in tablet dosage form by high performance liquid chromatography. J Chem Pharm Res 2011;3(4):893-8.

18. Al-Quim FF, Abdullah MD, Othman MR, Khalik WM. Development and validation of HPLC analytical method for mefenamic acid tablet (Ponstan). Int J Chem Sci 2014;12(1):62-72.

19. Dhumal BR, Bhusari KP, Tajne MR, Ghante MH, Jain NS. Stability indicating method for the determination of mefenamic acid in pharmaceutical formulations by HPLC. J Appl Pharm Sci 2014;4(12):60-4.

20. Natesan S, Thanasekaran D, Krishnaswami V, Ponusamy C. Improved RP-HPLC method for the simultaneous estimation of traxanamic acid and mefenamic acid in tablet dosage form. Pharm Anal Acta 2011;2(1):1-6.

21. Dahivelkar PP, Bari SB, Bhoir S, Bhagwat AM. High performance liquid chromatographic estimation of drotaverin hydrochloride and mefenamic acid in human plasma. Iran J Pharm Res 2009;8(3):209-15.

22. Niopas I, Mannzoridi K. Determination of indomethacin and mefenamic acid in plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1994;656(2):447-50.

23. Hedpara RJ, Chhatarala V, Agola A. A validated RP-HPLC method for the simultaneous estimation of paracetamol and dicyclomine hydrochloride in pharmaceutical formulations. JPSR 2013;4(6):2400-5.

24. Wahab SU. Development of RP-HPLC method for the simultaneous determination of mefenamic acid & drotaverine HCl combined tablet dosage form. Int J Pharm Sci 2011;3(1):115-7.

25. Saleh SF, Dereya SM, Omar MA. Stability-indicating HPTLC determination of mefenamic acid in bulk drug and pharmaceutical formulations. Int J Chem Anal Sci 2014;5(1):53-60.

26. Dhaneshwar SR, Jagtap VN. Development and validation of HPTLC method for the simultaneous estimation of mefenamic acid and paracetamol in combined dosage form. J Pharm Res 2012;5(8):4263-5.

27. Keer AR, Haveli SS, Gopani KH, Dhaneshwar SR. Application of high performance thin layer chromatography-densitometry for the determination of dicyclomine HCL in bulk drug and injection formulation. Der Pharm Chem 2011;3(1):549-56.

28. Patel TK, Meshram DB. Development and validation of high performance thin layer chromatography for estimation of mefenamic acid, paracetamol and dicyclomine HCl in tablet dosage form. Int J Pharm Sci Drug Res 2015;7(4):361-4.

29. Seetharaman R, Lakshmi KS. High performance thin layer chromatographic method for the simultaneous estimation of camylofin dihydrochloride and mefenamic acid in pharmaceutical tablet. Int J Pharm Pharm Sci 2014;6(1):585-9.

30. Mahadik M, Dhaneshwar S, Bhavsar R. A high performance liquid chromatography-tandem mass spectrometric method for the determination of mefenamic acid in human plasma: Application to pharmacokinetic study. Biomed Chromatogr 2012;26(10):1137-42.

31. Tan HS, Yan YP, Thio AF, Singh HS, Tan J. Stability-indicating capillary gas-liquid chromatographic assay of dicyclomine hydrochloride in some pharmaceutical formulations. J Chromatogr 1989;475(2):381-9.

32. ICH. Q2B Validation of analytical procedure: Methodology. International Conference on Harmonisation. Geneva: IFPMA; 2005.